Cell and gene therapies can change what’s possible for patients living with rare and severe diseases. Cost shouldn’t put that possibility out of reach.
CMS is expanding our Cell and Gene Therapy Access Model to help more Medicaid patients access these life-changing treatments. Learn more about the CGT 2.0 Model: